0.7324
8.45%
-0.0676
Phio Pharmaceuticals Corp stock is currently priced at $0.7324, with a 24-hour trading volume of 89,865.
It has seen a -8.45% decreased in the last 24 hours and a +11.95% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.778 pivot point. If it approaches the $0.712 support level, significant changes may occur.
Previous Close:
$0.80
Open:
$0.79
24h Volume:
89,865
Market Cap:
$3.36M
Revenue:
-
Net Income/Loss:
$-11.66M
P/E Ratio:
-0.0721
EPS:
-10.156
Net Cash Flow:
$-11.09M
1W Performance:
-4.88%
1M Performance:
+11.95%
6M Performance:
-25.27%
1Y Performance:
-82.09%
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Name
Phio Pharmaceuticals Corp
Sector
Industry
Phone
508 767 3861
Address
257 Simarano Drive, Suite 101, Marlborough, MA
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-05-20 | Initiated | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Stock (PHIO) Latest News
Phio Pharmaceuticals' (PHIO) Buy Rating Reiterated at HC Wainwright - Defense World
Defense World
Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID) - Yahoo Finance
Yahoo Finance
Phio Pharmaceuticals Corp. Forecasted to Post Q2 2024 Earnings of ($0.51) Per Share (NASDAQ:PHIO) - Defense World
Defense World
Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation ... - GlobeNewswire
GlobeNewswire
Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
GlobeNewswire Inc.
KalVista (KALV) Stock Continues to Decline: Here's Why - Yahoo Singapore News
Yahoo Singapore News
Phio Pharmaceuticals Corp Stock (PHIO) Financials Data
Phio Pharmaceuticals Corp (PHIO) Net Income 2024
PHIO net income (TTM) was -$11.66 million for the quarter ending September 30, 2023, a +4.41% increase year-over-year.
Phio Pharmaceuticals Corp (PHIO) Cash Flow 2024
PHIO recorded a free cash flow (TTM) of -$11.09 million for the quarter ending September 30, 2023, a +7.71% increase year-over-year.
Phio Pharmaceuticals Corp (PHIO) Earnings per Share 2024
PHIO earnings per share (TTM) was -$8.156 for the quarter ending September 30, 2023, a +24.24% growth year-over-year.
About Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Cap:
|
Volume (24h):